The small intestine plays an active role in regulating triglyceride-rich lipoprotein production, which is aberrantly upregulated in insulin-resistant states, increasing cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Intestinal TRL overproduction may elevate residual CV risk in T2D; hypothesis-generating for intestinal-targeted therapies pending trials.
Adeli et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: